摘要:
(4-oxy-3-(aryl)phenyl)pyridine compounds, in free or acid addition salt form, are useful as pharmaceuticals for treatment and prophylaxis of inflammation, particularly inflammatory or obstructive diseases of the airways, e.g. for asthma therapy. Preferred compounds are novel biphenyl pyridines, biphenyl benzamides and biphenyl phenylcarboxy compounds. The compounds are selective inhibitors of PDE 4 isoenzyme activity and also act to down regulate or inhibit TNF-&agr; release.
摘要:
The present invention relates to agents for anti-HIV infection, which contain, as an active ingredient, at least one photosensitizing dye selected from the group consisting of the compounds of the formulae (I) and (II): wherein R1, R2 and R3 are the same or different and each represents alkyl group having 1 to 4 carbon atoms, R4, R5 and R6 are the same or different and each represents alkyl group having 5 to 10 carbon atoms, and X− represents a physiologically acceptable monovalent anion. The present invention also relates to a method for treating or preventing HIV infection diseases, which includes administering the photosensitizing dye. A daily dose of the photosensitizing dye is usually 2 to 100 &mgr;g, and preferably 5 to 40 &mgr;g, per kg body weight. Administration of the photosensitizing dye to HIV infected subjects leads to improvement or cure of the symptoms of AIDS related complex and increase in CD4-positive lymphocytes, which is effective for the treatment of HIV infection diseases.
摘要:
The present invention relates to the combination of the 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor (HMG-CoA inhibitor) cerivastatin with fibrates and its use in the prophylaxis and treatment of disorders of lipid metabolism.
摘要:
The invention relates to a compound of formula (I): wherein: A represents pyridine, pyridinium or piperidine R1, R2, R3 and R4 are as defined in the description R5 represents hydrogen, a nitrogen-containing heterocycle or a group of formula (II): R6 represents hydrogen or linear or branched (C1-C6)alkyl. and medicinal products containing the same which are useful in treating pain or deficiencies in memory.
摘要:
The present invention relates to novel compounds of Formula I which are useful in inhibiting protein isoprenyl transferases and the farnesylation or geranylgeranylation of the oncogene protein Ras and other related small g-proteins, and compositions containing such compounds and methods of using such compounds.
摘要:
The invention disclosed some 1,4-dihydropiridine derivative chemically with guaiacoxypropanolamine based phenoxypropanolamine moiety and pharmacologically with &bgr;-adrenoceptor blocking and partial &bgr;2-agonist activities, is now emerging. The compound of 1,4-dihydropiridine derivative wherein has the formula I, wherein R selected from four group as follow R1 selected from X, H, NO2 saturated C1-C6 alkyl chain, unsaturated C6-C6 alkyl chain, R2 selected from H, CH3 R3 and R4 are individually selected from saturated C1-C6 alkyl chain, unsaturated C1-C6 alkyl chain; R5 selected from OH, saturated C1-C6 alkyl chain, unsaturated C1-C6 alkyl chain.
摘要:
The invention relates to a method of crystallizing a tetrahydropyridine derivative, to the novel crystalline forms thereby obtained and to the pharmaceutical compositions containing said tetrahydropyridine derivative in a given crystalline form as the active principle.
摘要:
The present invention provides medicines for treating cardiac insufficiency which contain as an active ingredient indane derivatives of formula (I) wherein R1 represents hydrogen atom, nitro group, cyano group, C1-6 alkylcarbonylamino, R2 and R3 each independently represent C1-6 alkyl group, R4 represents hydroxyl group or C1-6 alkylcarbonyloxy group or represents a bond or oxygen atom together with R5, R5 represents hydrogen atom or represents a bond or oxygen atom together with R4, R6 represents hydrogen atom, hydroxyl group or NR7R8, n means 0 or an integer of 1 to 4, X represents C═O, CH2, SO2 or NR16, Y represents NR17 when X is C═O, CH2 or SO2 and represents C═O when X is NR16, Z is absent when Y represents NR17 or represents NR18 when Y is C═O, W represents aromatic groups or lactam rings, or pharmaceutically acceptable salt thereof.